Chronic Lower Back Pain Market Size, Epidemiology, Treatment, Therapies and Companies by DelveInsight

(Albany, US) DelveInsight added a new report titled Chronic Lower Back Pain (CLBP) Market Insights, Epidemiology and Market Forecast–2030 to its portfolio.

DelveInsight's ‘Chronic Lower Back Pain Market Insights, Epidemiology and Market Forecast–2030' report proffers an in-depth understanding of Chronic Lower Back Pain, its etiology, and manifestations, a detailed analysis of the disease historical as well as forecasted epidemiology trends, its prevalence, incidence and patient pool. The report covers the comprehensive layout of the available marketed or approved therapies for CLBP and the upcoming therapies in the pipeline in the Chronic Lower Back Pain market with unmet needs, market drivers and barriers that may impact the growth of the market size in the next decade in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Moreover, the Chronic Lower Back Pain Market Insights report lays in front the therapy that has the potential to occupy the significant chunk of the CLBP market, competitors' analysis, key collaborations, licensing opportunities, R&D scenario and influential non-profit organizations working for CLBP patients' relief. 

Some key facts of Chronic Lower Back Pain Market:

  • Chronic Lower Back Pain Market landscape involves 15+ companies actively working in advancing CLBP market.
  • Of the emerging therapies, Braeburn Pharmaceuticals/Camurus, Pfizer/Eli Lilly and Company, Mesoblast, Egalet Corporation are expected to launch their respective products, during the forecast period.
  • Supportive treatment regimens entirely dominate the current CLBP market size along with the drugs that have been approved to treat comorbidities associated with CLBP, and those that are approved for chronic pain usually.
  • The current opioid prescription market is expected to decline in the coming years because CLBP patients will switch from currently prescribed opioids to emerging opioid therapies, such as Buprenorphine and Egalet‐002.
  • Limited Chronic Lower Back Pain treatment options are the major market driving forces in the CLBP market.

Request a sample page: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market

View Report: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market

Lower back pain is a common ailment, and at everyone at a certain point of time must have felt it. However, if the pain persists for more than 3-months, it is referred to as chronic lower back pain and is the second leading cause of the disability and degraded quality of life worldwide. The origin, as well as the intensity of the pain, may vary from an injury, disease to stress and from mild to severe.

Chronic Lower Back Pain Epidemiology

According to DelveInsight's analysis, the total CLBP prevalent population in the 7MM was observed to be 73,802,461 in 2017, which is expected to increase during the study period, i.e., 2017–2030. A higher percentage of diagnosed prevalence was observed for females in comparison to males, in all the 7MM countries, except Japan, wherein males occupy a larger patient pool than females. Also, it has been observed that CLBP is mostly diagnosed in the age group of 40–69.

Present therapies in the CLBP market only provide temporary relief from the pain. At present, the Chronic Lower Back Pain market is dominated by opioids. However, the long-term opioid use results in addiction; hence the current scenario demands products with better safety profile and improved Quality of Life (QoL).

The report offers exhaustive coverage of the marketed as well as the emerging drugs.

Chronic Lower Back Pain Marketed Drugs

  • Cymbalta: Eli Lilly and Company
  • Xtampa: Collegium Pharmaceutical
  • Butrans: Purdue Pharma
  • Belbuca: BioDelivery Sciences International
  •  And many others

Request a sample page: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market

View Report: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market

Chronic Lower Back Pain Drugs in Pipeline:

  • Tanezumab: Eli Lilly/Pfizer
  • Fasinumab: Regeneron Pharmaceuticals/ Teva Pharmaceuticals
  • MPC-06-ID: Mesoblast
  • Egalet‐002 (Egalet Corporation)
  • AXS‐02 (Axsome Therapeutics)
  • ALLOD‐2 (Allodynic Therapeutics)
  • ASP7962 (Astellas Pharma)
  • CAM2038 (Braeburn Pharmaceuticals/Camurus)
  • Clonidine Micropellets (Sollis Therapeutics)
  • NKTR‐181 (Nektar Therapeutics)
  • GRT6005: Grünenthal GmbH
  • AB001: Frontier Biotechnologies
  • IDCT (DiscGenics)
  • YH14618 (Yuhan Corporation)
  • SP‐102 (Semnur Pharmaceuticals)
  • SX600 (SpineThera)
  •  And many others

Have a look at the sample report: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market

View Report: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market

Scope of the Chronic Lower Back Pain Market Report

  • Geography Covered: The United States, EU5 (Germany, Spain, Italy, France, and The United Kingdom), and Japan
  • Study Period: 3-year historical and 11-year forecasted analysis (2017-2030)
  • Epidemiology Segmentation: Gender-Specific, Age-Specific, Severity Specific, Total diagnosed etc.
  • Markets Segmentation: By Geographies, By therapies
  • Companies Covered: Braeburn Pharmaceuticals, Camurus, Regeneron Pharmaceuticals, Teva Pharmaceutical, Pfizer, Eli Lilly and Company, Mesoblast, Egalet Corporation, Axsome Therapeutics, Allodynic Therapeutics, Astellas Pharma, Grünenthal GmbH, Frontier Biotechnologies, DiscGenics, Yuhan Corporation, Semnur Pharmaceuticals, Sollis Therapeutics, SpineThera, Stayble Therapeutics, AnGes MG, Asahi Kasei Pharma, and others.
  • Comparative Analysis: Comparative and conjoint analysis of emerging therapies.
  • Case Studies
  • KOL's Views

Request a WebEx walkthrough of the report: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market

Reason to purchase

  • Bespoke primary and secondary research
  • 24*7 post-sale customer support
  • Option for customizing and personalizing research reports as per needs

Table of Contents

1

Key Insights

2

Chronic Lower Back Pain (CLBP) Market Overview at a Glance

3

Executive Summary

4

SWOT Analysis

5

Chronic Lower Back Pain - Disease Background and Overview

6

Chronic Lower Back Pain Epidemiology Methodology

7

Chronic Lower Back Pain Epidemiology and Patient Population

8

United States-specific Chronic Lower Back Pain Epidemiology

9

Japan-specific Chronic Lower Back Pain Epidemiology

10

Chronic Lower Back Pain Treatment Algorithm, Current Treatment, and Medical Practices

11

Proposed Guidelines for Chronic Lower Back Pain

12

Unmet Needs in Chronic Lower Back Pain Market

13

Chronic Lower Back Pain Marketed Products

14

Chronic Lower Back Pain Emerging Therapies

15

Chronic Lower Back Pain Market Forecast Methodology

16

Chronic Lower Back Pain - 7MM Market Analysis

17

Conjoint Analysis

18

United States: Chronic Lower Back Pain Market Outlook

19

EU-5 countries: Chronic Lower Back Pain Market Outlook

20

Japan: Chronic Lower Back Pain Market Outlook

21

Case Reports

22

Chronic Lower Back Pain Market Drivers

23

Chronic Lower Back Pain Market Barriers

24

Appendix

25

DelveInsight Capabilities

26

Disclaimer

 

DelveInsght’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.

Related Reports:

Related Blogs:

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Know more about our competitive intelligence services.

Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/
Connect With Us at:
LinkedIn | Facebook | Twitter

 

Comments

Post a Comment

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

What is Competitive intelligence service? Competitive intelligence ideally means gathering information on rival business in the market, analyse the information and use the information to strategize to yield positive results. Going by the definition, competitive intelligence assembles actionable information from diverse published and unpublished sources, collected efficiently and ethically. So, analysts performing Competitive intelligence for their clienteles present a detailed picture of the marketplace, forthcoming challenges and the ways to face them, even before the can harm the client’s business. What could it mean? Competitive intelligence can often give a wrong idea, as it may misunderstood as a service which can help gain an advantage over the rivals. However, this is not the case. Competitive intelligence is an ethical and legal practise undertaken involving the study of analytical data, analysing the market and optimizing the relevant and realistic strategies t...
Read more

Cervical Intraepithelial Neoplasia Market and Epidemiology 2032 by DelveInsight

DelveInsight's " Cervical Intraepithelial Neoplasia Market Insights, Epidemiology, and Market Forecast-2032 " report delivers an in-depth understanding of Cervical Intraepithelial Neoplasia, historical and forecasted epidemiology as well as the Cervical Intraepithelial Neoplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Cervical Intraepithelial Neoplasia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cervical Intraepithelial Neoplasia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Cervical Intraepithelial Neoplasia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Cervical Intraepithelial Neoplasia market. Request for a Free Sample Report: Cervic...
Read more

The Need And The Importance Of The Healthcare Reports for the Pharma Companies

Image
It is very important for the hospitals and the other medical institutions to preserve and keep the healthcare reports of all the patients very safe and secure. All the medical records are being kept by almost all of these institutes. As a matter of fact, the healthcare reports are very important for comprehending the medical history of the patient. If he or she suffers from the same ailment once more the previous reports will be absolutely indispensible while treating him or her. Nowadays, with the advancement of technology the manual records are slowly and gradually getting digitalized. It is easier to store and preserve the digital records than the manual and the physical ones.  Choosing The Best And The Most Professional Services For Healthcare Reports: • Rising Pharma Market for You Now In the market there are a host of companies that preserves the healthcare reports of the various patients. All of it is now being done in the digital format due to the adv...
Read more